Chicharros USA - bolsa internacional

SPHS

Templarium ¿nos la meterán doblada las Sofiris, o no?, toca esperar al lunes. Por lo pronto, ni noticias, ni tele, ni ná.

SPHS

Qué difícil es este mundo, donde nunca sabes qué es verdad y qué es mentira... de todas formas, vamos a confiar que el lunes pueda ser un día positivo...

Desde luego, dejamos un nefasto viernes con los acontecimientos de París... El mundo se desintegra...

MSTX 0.417 $ -0.008 (-1.88%)
$3.00 price target
In a research report issued Friday, Canaccord analyst John Newman reiterated a Buy rating on shares of Mast Therapeutics Inc (NYSEMKT:MSTX), with a $3.00 price target, after the company reported its third-quarter results and outlined its ambitious clinical development strategy for its pipeline in its conference call yesterday.
We are slightly lowering our FY15 EPS estimate to $(0.23) from $(0.22) due to higher R&D spending,” the analyst concluded.
http://www.smarteranalyst.com/2015/11/13/canaccord-reiterates-buy-on-mast-therapeutics-inc-following-3q15-update/
---
Con un RSI intradia en 36 y en semanal en 41.39, en mensual en suelo durmiente, vaya cumple los parametros de libro para entrada en largo plazo y aunque las MM no dan señal de compra pero el RSI sí , y buscando el medio plazo digamos que para Febrero o tal vez finales de año 2015 a esta se le puede sacar casi seguro un 50 % pues ha regresado al soporte de largo plazo su AF con 2 OD con derecho de monopolio por 7 años en Europa y USA de una de ellas, es atractivo pues las expectativas de mercado no son despreciables, y por mucho que retroceda su situación financiera no es tan grave,a pesar del aumento de los gastos, lo que mas puede suceder es que metan otro Offering ATM como ya hace un año hicieron casualmente a través Canaccord , para poder financiar tranquilamente la F III que tienen pendiente en ambas Orphan Drug , pero antes de Offering seguro que va a soltar un par de Good News para poder soltar el Offering a precios mal altos
---
http://stockcharts.com/h-sc/ui

Pues si tiene que ser positivo el PRE no va muy alegre que digamos....como siga la senda del viernes me da ami que salgo por patas...

Se sabe algo en los foros usanos??

SPHS

CTIX

Cellceutix Selects Docetaxel for Combination Arm in Planned Phase 2 Trial for Ovarian Cancer

BEVERLY, MA--(Marketwired - November 16, 2015) - Cellceutix Corporation (OTC: CTIX) (the "Company"), a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, anti-inflammatory and antibiotic applications, today reports that, based upon ongoing laboratory studies, the Company intends to use docetaxel for the combination therapy arm in the planned Phase 2 clinical trial to treat patients with platinum-resistance ovarian cancer. Cellceutix is designing the multi-arm study to evaluate Kevetrin as a monotherapy and as a component of combination therapy.

In planning the combination therapy arm of the study, several different chemotherapies were tested with Kevetrin. Nude mice were implanted with a human ovarian cancer tumor. After tumors were established, mice were treated with 200 mg/kg of Kevetrin in combination with docetaxel at 15 or 30 mg/kg. Interim findings showed that mice treated with Kevetrin in combination with 15 mg/kg docetaxel exhibited a significant reduction in tumor growth. Kevetrin in combination with 30 mg/kg docetaxel further reduced tumor burden.

Cellceutix finds it encouraging that 6 of 10 tumors in the group treated with the combination of Kevetrin and 30 mg/kg docetaxel have been reduced to the point that they are not measurable.

The experiment is still ongoing. The determination of the final docetaxel dose has not yet been determined, as the Company needs to take into consideration docetaxel toxicity. The final data from the research will be used to support the planned Phase 2 trial, which remains subject to Food and Drug Administration (FDA) guidance and authorization to initiate the trial.

SPHS

NO leo nada destacado, Nacmorn, salvo el optimismo que parece ser bastante superior al pesimismo.. Ojalá sea simplemente un recorte lógico tras una subida tan brutal... La banda estimada de 4-6 dólares es la que parece que gana en la previsión de precios objetivos... Ojalá...

ONTY

Oncothyreon to Present Updated Data on ONT-380 for the Treatment of HER2-Positive Breast Cancer at the San Antonio Breast Cancer Symposium

SEATTLE, Nov. 16, 2015 (GLOBE NEWSWIRE) -- Oncothyreon Inc. (Nasdaq:ONTY), a clinical-stage biopharmaceutical company dedicated to the development of oncology products that can improve the lives and outcomes of patients, today announced that data from the company's ongoing trials of ONT-380, an orally active, reversible and selective small-molecule HER2 inhibitor being developed for the treatment of metastatic breast cancer, will be presented at the upcoming San Antonio Breast Cancer Symposium (SABCS) being held December 8-12, 2015 in San Antonio, TX.

"We are looking forward to presenting additional and updated clinical trial data on ONT-380 for the treatment of patients with HER2-positive breast cancer, including an analysis of patients that suffer from central nervous system (CNS) metastases, at SABCS," said Robert L. Kirkman, M.D., President and CEO of Oncothyreon. "CNS metastases impact up to 50 percent of women with HER2-positive metastatic breast cancer and represent a major unmet medical need. ONT-380 is an exciting molecule that has the potential to provide a much needed treatment option for this patient population."

The SABCS presentation details are as follows:

A phase 1b study of ONT 380, an oral HER2-specific inhibitor, combined with ado trastuzumab emtansine (T DM1), in HER2+ metastatic breast cancer (MBC)

First Author: Cristiano Ferrario, Segal Cancer Centre, Jewish General Hospital, Montreal, QC
Date/Time: Friday, December 11, 2015 at 7:30-9:00 a.m. CT
Session: Poster Session 4: Treatment: HER2-Targeted Therapy
Abstract P4-14-20

ONT-380 in the treatment of HER2+ breast cancer central nervous system (CNS) metastases (mets)

First Author: Rashmi Krishna Murthy, MD Anderson Cancer Center, Houston, TX
Date/Time: Friday, December 11, 2015 at 7:30-9:00 a.m. CT
Session: Poster Session 4: Treatment: HER2-Targeted Therapy
Abstract P4-14-19

SPHS

Yo tampoco leo nada nuevo, habrá que esperar a la apertura, igual se da la vuelta como un calcetín.